SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

Fatty acid-binding protein-4 as a biomarker predicting acromegaly-associated diabetes mellitus

Mustafa ÖZBEK
Erman ÇAKAL
Muhammed Erkam SENCAR
Murat ÇALAPKULU
Davut SAKIZ
İlknur ÖZTÜRK ÜNSAL
Sema HEPŞEN
Pınar AKHANLI
Hakan DÜĞER
Bekir UÇAN
Seyit Murat BAYRAM
Pages
2592–2599
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The FABP-4 may be a helpful predictor of acromegaly-associated DM.Key words: Acromegaly, adipokin, FABP-4, diabetes mellitus

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The known pathogenesis of diabetes mellitus (DM) in acromegaly is mainly based on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess.
📊
Key Findings & Data:Fatty acid-binding protein 4 (FABP-4), a novel adipokine, is found to induce insulin resistance and type 2 DM.
💡
Conclusion & Impact:Conclusion: The FABP-4 may be a helpful predictor of acromegaly-associated DM.Key words: Acromegaly, adipokin, FABP-4, diabetes mellitus
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: The known pathogenesis of diabetes mellitus (DM) in acromegaly is mainly based on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess. Fatty acid-binding protein 4 (FABP-4), a novel adipokine, is found to induce insulin resistance and type 2 DM. We aimed to investigate the possible effect of FABP-4 on glucose metabolism in patients with acromegaly. Materials and methods: This case-control study included 28 patients newly diagnosed with acromegaly and 57 healthy volunteers. The patients with acromegaly were classified according to their glycemic status as with DM, prediabetes, and normal glucose tolerance. Anthropometric measurements, laboratory test results, and FABP-4 levels of the subjects were evaluated. Results: Although no difference was observed in FABP-4 levels between acromegaly and control groups, the FABP-4 level was higher in the patients with acromegaly having DM compared to the patients with acromegaly having prediabetes and NGT, and the control group (p = 0.004, p = 0.001, p = 0.004, respectively). Logistic regression analysis suggested that the FABP-4 is an independent predictor of DM in acromegaly (β = 7.382, OR = 38.96, 95% CI: 1.52-5.76, p = 0.018). Conclusion: The FABP-4 may be a helpful predictor of acromegaly-associated DM.Key words: Acromegaly, adipokin, FABP-4, diabetes mellitus

🔖

Cite This Article

ÖZBEK, M., ÇAKAL, E., SENCAR, M. E., ÇALAPKULU, M., SAKIZ, D., ÜNSAL, İ. Ö., HEPŞEN, S., AKHANLI, P., DÜĞER, H., UÇAN, B., BAYRAM, S. M. (2022). Fatty acid-binding protein-4 as a biomarker predicting acromegaly-associated diabetes mellitus. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2592–2599. https://ajindex.com/articles/609348

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary 2017
  2. 20 (1): 4–9. doi:10.1007/s11102-016-0754-x 2. Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Frontiers of Hormone Research 2018
  3. 20–28. doi:10.1159/000486001 3. Gözü HI, Öztaş D, Güleryüzlü Y, Volkan Ö, Dündar C et al. Evaluation of cardiovascular parameters in acromegalic patients. Turkish Journal of Endocrinology and Metabolism 2007
  4. 6 4. Dreval A V, Trigolosova I V, Misnikova I V, Kovalyova YA, Tishenina RS et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocrine Connections 2014
  5. 3 (2): 93–98. doi:10.1530/EC-14-0021 5. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014
  6. 17 (1): 81–89. doi:10.1007/s11102- 013-0471-7 6. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology 2011
  7. 164 (6): 877–884. doi:10.1530/EJE-10- 1050 7. Ferraù F, Albani A, Ciresi A, Giordano C, Cannavò S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Frontiers in Endocrinology 2018
  8. doi:10.3389/fendo.2018.00358 8. Olarescu NC, Bollerslev J. The impact of adipose tissue on insulin resistance in acromegaly. Trends in Endocrinology and Metabolism 2016
  9. 27 (4): 226–237. doi:10.1016/j. tem.2016.02.005 9. Trojnar M, Patro-Małysza J, Kimber-Trojnar Ż, LeszczyńskaGorzelak B, Mosiewicz J. Associations between Fatty AcidBinding Protein 4−A proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells 2019
  10. 8 (3): 227. doi:10.3390/cells8030227 10. Zhang Y, Zhang H-H, Lu J-H, Zheng S-Y, Long T et al. Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy. Journal of Diabetes Investigation 2016
  11. 7 (5): 797–804. doi:10.1111/jdi.12484 11. Li J-C, Wu D-A, Hou J-S, Subeq Y-M, Chen H-D et al. High serum adipocyte fatty acid binding protein is associated with metabolic syndrome in patients with type 2 diabetes. Journal of Diabetes Research 2016
  12. 8380279. doi:10.1155/2016/8380279 12. Djoussé L, Gaziano JM. Plasma levels of FABP